LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 25,100 shares, a decrease of 17.2% from the January 31st total of 30,300 shares. Based on an average daily volume of 435,300 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the company’s stock are sold short.

Hedge Funds Weigh In On LAVA Therapeutics

Several large investors have recently made changes to their positions in LVTX. Virtu Financial LLC acquired a new stake in LAVA Therapeutics in the third quarter valued at approximately $32,000. BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics during the 4th quarter valued at approximately $40,000. Finally, Sanofi acquired a new stake in LAVA Therapeutics in the 4th quarter valued at $1,825,000.

LAVA Therapeutics Trading Up 2.1 %

Shares of LVTX stock traded up $0.03 during mid-day trading on Friday, reaching $1.44. The stock had a trading volume of 204,504 shares, compared to its average volume of 198,833. LAVA Therapeutics has a 1-year low of $0.85 and a 1-year high of $4.21. The firm has a market cap of $37.86 million, a price-to-earnings ratio of -1.40 and a beta of 0.48. The business’s fifty day moving average is $1.02 and its 200-day moving average is $1.42.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Tuesday, December 10th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.11). On average, analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on LVTX. HC Wainwright restated a “neutral” rating and set a $1.50 target price (down previously from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, LAVA Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.